What 8 Analyst Ratings Have To Say About Genmab
What 8 Analyst Ratings Have To Say About Genmab
關於genmab，8位分析師的評級是怎樣的？
The...8 analysts have expressed a variety of opinions on Genmab (NASDAQ:GMAB) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度中，8位分析師對Genmab（納斯達克股票代碼：GMAB）表達了各種觀點，從看漲到看跌，提出了各種各樣的觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Genmab, revealing an average target of $50.0, a high estimate of $53.00, and a low estimate of $47.00. This upward trend is apparent, with the current average reflecting a 1.01% increase from the previous average price target of $49.50.
分析師已經爲Genmab設定了12個月的目標股價，顯示平均目標股價爲50.0美元，最高估計爲53.00美元，低估值爲47.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的平均目標價49.50美元上漲了1.01％。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
The...
通...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間